FI3619204T3 - Yhdisteitä hengitystiesairauksien hoitoon - Google Patents

Yhdisteitä hengitystiesairauksien hoitoon

Info

Publication number
FI3619204T3
FI3619204T3 FIEP18795097.7T FI18795097T FI3619204T3 FI 3619204 T3 FI3619204 T3 FI 3619204T3 FI 18795097 T FI18795097 T FI 18795097T FI 3619204 T3 FI3619204 T3 FI 3619204T3
Authority
FI
Finland
Prior art keywords
polymorph
solvate
salt
compound
group
Prior art date
Application number
FIEP18795097.7T
Other languages
English (en)
Finnish (fi)
Inventor
Spencer Williams
Sayali Shah
Zalihe Hakki
Alastair Stewart
Original Assignee
Tianli Biotech Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017901611A external-priority patent/AU2017901611A0/en
Application filed by Tianli Biotech Pty Ltd filed Critical Tianli Biotech Pty Ltd
Application granted granted Critical
Publication of FI3619204T3 publication Critical patent/FI3619204T3/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
FIEP18795097.7T 2017-05-03 2018-05-03 Yhdisteitä hengitystiesairauksien hoitoon FI3619204T3 (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2017901611A AU2017901611A0 (en) 2017-05-03 Compounds for the treatment of respiratory diseases
AU2017901647A AU2017901647A0 (en) 2017-05-05 Compounds for the treatment of respiratory diseases
PCT/AU2018/050404 WO2018201192A1 (en) 2017-05-03 2018-05-03 Compounds for the treatment of respiratory diseases

Publications (1)

Publication Number Publication Date
FI3619204T3 true FI3619204T3 (fi) 2025-11-06

Family

ID=64015663

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP18795097.7T FI3619204T3 (fi) 2017-05-03 2018-05-03 Yhdisteitä hengitystiesairauksien hoitoon

Country Status (8)

Country Link
US (2) US20200079757A1 (enExample)
EP (1) EP3619204B1 (enExample)
JP (1) JP2023134493A (enExample)
CN (1) CN110753688A (enExample)
AU (3) AU2018262108A1 (enExample)
FI (1) FI3619204T3 (enExample)
PT (1) PT3619204T (enExample)
WO (1) WO2018201192A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4591936A3 (en) 2015-03-23 2025-10-15 Tianli Biotech Pty Ltd Treatment of respiratory diseases
WO2020093098A1 (en) * 2018-11-07 2020-05-14 The University Of Melbourne Novel compounds for the treatment of respiratory diseases
CN110452880B (zh) * 2019-09-09 2021-09-21 温州医科大学附属第一医院 急性肺损伤细胞模型的制备方法及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593992A (en) * 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
US5593991A (en) * 1993-07-16 1997-01-14 Adams; Jerry L. Imidazole compounds, use and process of making
US5658903A (en) * 1995-06-07 1997-08-19 Smithkline Beecham Corporation Imidazole compounds, compositions and use
US6335340B1 (en) * 1997-12-19 2002-01-01 Smithkline Beecham Corporation compounds of heteroaryl substituted imidazole, their pharmaceutical compositons and uses
EP2493876B1 (en) * 2009-10-28 2014-02-12 Pfizer Inc Imidazole derivatives as casein kinase inhibitors
CZ2012538A3 (cs) * 2012-08-08 2014-02-19 Masarykova Univerzita Inhibitory pro léčbu B-buněčné chronické lymfocytární leukémie
EP4591936A3 (en) * 2015-03-23 2025-10-15 Tianli Biotech Pty Ltd Treatment of respiratory diseases

Also Published As

Publication number Publication date
AU2022202774A1 (en) 2022-05-19
JP2023134493A (ja) 2023-09-27
PT3619204T (pt) 2025-10-29
AU2024200521A1 (en) 2024-02-15
US20200079757A1 (en) 2020-03-12
EP3619204A1 (en) 2020-03-11
US20220380343A1 (en) 2022-12-01
AU2018262108A1 (en) 2019-11-21
WO2018201192A1 (en) 2018-11-08
AU2024200521B2 (en) 2025-10-02
EP3619204A4 (en) 2021-03-24
EP3619204B1 (en) 2025-10-01
JP2020518621A (ja) 2020-06-25
CN110753688A (zh) 2020-02-04

Similar Documents

Publication Publication Date Title
CL2023000196A1 (es) Compuestos de tetrahidropirazolo-pirazinil-dihidroimidazolona o tetrahidropirazolo-piridinil-dihidroimidazolona y métodos de uso de los mismos
DOP2020000037A (es) Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
PH12019500395A1 (en) Amino-pyrrolopyrimidinone compounds and methods of use thereof
CL2021000038A1 (es) Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona y su uso en el tratamiento de trastornos dependientes de la proteína con dedos de zinc 2 de la familia ikaros (ikzf2)
JP2019504050A5 (enExample)
EA202191801A1 (ru) Гетероциклические ингибиторы mat2a и способы применения для лечения рака
MX2020005363A (es) Compuestos heterociclicos como inhibidores de prmt5.
MX2020005874A (es) Acidos carbamoil ciclohexilicos n-enlazados a pirazol como antagonistas de receptores del acido lisofosfatidico (lpa).
ES2655091T3 (es) Derivados del ácido pirrolidíncarboxílico como agonistas del receptor 43 acoplado a proteína G (GPR43), composición farmacéutica y métodos para su uso en el tratamiento de trastornos metabólicos
JP2016506369A5 (enExample)
AR073209A1 (es) Tienopirimidinas utiles para la profilaxis y/o tratamiento de enfermedades influenciadas por la inhibicion de quinasas mnk1 y/o mnk2 ,tales como enfermedades metabolicas y trastornos inflamatorios,y composiciones farmaceuticas que las contienen.
JP2017501237A5 (enExample)
PE20141148A1 (es) Mesilato de n-[5-(aminosulfonil)-4 metil-1-3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida monohidrato
HRP20210847T1 (hr) Supstituirani derivati indola kao inhibitori replikacije denga virusa
FI3619204T3 (fi) Yhdisteitä hengitystiesairauksien hoitoon
FI3546462T3 (fi) Uusi oksoisokinoliinijohdannainen
EA202190395A1 (ru) Замещенные гетероарилом сульфонамидные соединения и их применение в качестве терапевтических средств
IL276711B1 (en) Arginase inhibitors and methods of use thereof
EA201590021A1 (ru) Новые замещенные производные 1,3-дигидро-2h-бензимидазол-2-она, замещенные гетероциклами, в качестве противовирусных средств против респираторного синцитиального вируса
RU2019123404A (ru) Производное пиримидина
CY1120530T1 (el) Απο του στοματος χορηγησιμη φαρμακευτικη συνθεση
RU2017117566A (ru) Активатор kcnq2-5 каналов
MX2020010866A (es) Compuestos novedosos utiles como abridores del canal de potasio.
MX2022003617A (es) Derivados heterociclicos, composiciones farmaceuticas y su uso en el tratamiento o mejora del cancer.
UY39799A (es) Compuestos de pirrolil–sulfonamida